Despite the different effects of HER4 knockout in three luminal cell lines, abemaciclib treatment proved to be most efficient in all three ESR-positive cell lines and seems to be superior over tamoxifen for the treatment of ESR-positive BC. Here, ERBB4 is linked to breast cancer.